Select Page


On June 24, 2015, the Food and Drug Administration warned that Daytrana, a pharmaceutical patch approved to treat attention deficit hyperactivity disorder (ADHD), can cause permanent skin discoloration. The FDA describes the condition as “disfiguring” and urged doctors to consider alternate methods.

Therefore, people affected by this lifelong side effect should speak with an attorney about their options. You may be entitled to compensation for this condition. Speak with an attorney at the Michael Brady Lynch Firm today.


FDA Documents Dozens of Daytrana Cases

daytranaIn the FDA’s June 2015 alert, the agency said it had discovered more than 50 reports of Daytrana users suffering from a condition called chemical leukoderma. In all cases, the discoloration was permanent.

Repeated exposure to certain chemicals causes chemical leukoderma. According to the FDA, it can develop anywhere from a few months to several years after beginning use of the Daytrana patch. Some discolored patches of skin were as large as eight inches in diameter.

In most instances, the discoloration was limited to the area where the patch was placed. However, the FDA noted that some patients experienced discoloration in parts of the body where the patch was never applied.


What an Attorney Can Do

These skin problems detailed by the FDA are far more than a simple side effect. They are permanent, and those affected will live with this for the rest of their lives.

If you knew that Daytrana was going to leave a part of your body permanently discolored, would you have chosen to take it? If you weren’t adequately warned about the side effects of Daytrana, you may have a legal case.

An attorney will tell you your options if Daytrana harmed you or someone you love. Call us anytime at (877) 513-9517 or fill out the form on this page for a free case evaluation from an experienced pharmaceutical drug attorney.

We’ll let you know what we can do to help at no cost and with no obligation.


Learn More

Noven Recalls Daytrana Patches

ADHD Medication Daytrana Linked to Permanent Skin Discoloration

Medical Devices

Zantac Multidistrict Litigation Update

Zantac belongs to a group of medications known as histamine-2 blockers. These drugs reduce acid production in the stomach for those diagnosed with gastroesophageal reflux disease (GERD), Zollinger Ellison syndrome, and other conditions causing heartburn and ulcers.

RoundUp Litigation Update August 2022

The RoundUp Litigation still has over 40,000 unresolved claims by claimants with NHL from being exposed to the herbicide. More plaintiffs are taking to trial to obtain the amount of compensation that they rightly deserve. [1] As of August 15, 2022, 4,116 cases are still pending in the MDL. [2]

What Our Clients Are Saying